Koers Mabvax Therapeutics Holdings Inc Nasdaq
Aandelen
US87959M2089
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2016 | 148K 137K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,36 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,76 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,61 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 436K | Nettoschuld 2017 | 2,48 mln. 2,3 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,58% | 122 mld. | |
+16,60% | 113 mld. | |
+17,55% | 26,22 mld. | |
-24,33% | 19,01 mld. | |
-19,14% | 15,71 mld. | |
-17,95% | 15,22 mld. | |
-46,81% | 14,72 mld. | |
+58,78% | 14,58 mld. | |
+4,91% | 13,84 mld. |
- Beurs
- Aandelen
- Koers MBVXQ
- Koers